Novel therapeutic approaches to cryoglobulinemia: Imatinib, infliximab, bortezomib, and beyond

Giampaolo Talamo, Maurizio Zangari

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Cryoglobulinemia is a rare disorder characterized by the development of leukocytoclastic necrotizing vasculitis. Currently, the conventional treatment of cryoglobulinemia in the absence of viral infection involves corticosteroids, immunosuppressive drugs, and plasma exchange. Patients with relapsed or refractory disease require additional therapies, but no established guidelines regarding the treatment of these patients are available. The recent molecular revolution has resulted in an armamentarium of targeted biologic agents, and several of these novel drugs have been shown to be active in patients with refractory cryoglobulinemia. This chapter reviews the clinical results and rationale of several emerging agents for cryoglobulinemia, including TNF inhibitors, the immunomodulator drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib.

Original languageEnglish (US)
Title of host publicationHCV Infection and Cryoglobulinemia
PublisherSpringer-Verlag Italia s.r.l.
Pages349-355
Number of pages7
Volume9788847017054
ISBN (Electronic)9788847017054
ISBN (Print)8847017041, 9788847017047
DOIs
StatePublished - Apr 1 2012

Fingerprint

Cryoglobulinemia
Pharmaceutical Preparations
Proteasome Inhibitors
Plasma Exchange
Thalidomide
Immunologic Factors
Biological Factors
Virus Diseases
Therapeutics
Immunosuppressive Agents
Adrenal Cortex Hormones
Guidelines
Infliximab
Bortezomib
Imatinib Mesylate

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Talamo, G., & Zangari, M. (2012). Novel therapeutic approaches to cryoglobulinemia: Imatinib, infliximab, bortezomib, and beyond. In HCV Infection and Cryoglobulinemia (Vol. 9788847017054, pp. 349-355). Springer-Verlag Italia s.r.l.. https://doi.org/10.1007/978-88-470-1705-4_45
Talamo, Giampaolo ; Zangari, Maurizio. / Novel therapeutic approaches to cryoglobulinemia : Imatinib, infliximab, bortezomib, and beyond. HCV Infection and Cryoglobulinemia. Vol. 9788847017054 Springer-Verlag Italia s.r.l., 2012. pp. 349-355
@inbook{7af9a05ab44f44d4a10262c5e1f91b74,
title = "Novel therapeutic approaches to cryoglobulinemia: Imatinib, infliximab, bortezomib, and beyond",
abstract = "Cryoglobulinemia is a rare disorder characterized by the development of leukocytoclastic necrotizing vasculitis. Currently, the conventional treatment of cryoglobulinemia in the absence of viral infection involves corticosteroids, immunosuppressive drugs, and plasma exchange. Patients with relapsed or refractory disease require additional therapies, but no established guidelines regarding the treatment of these patients are available. The recent molecular revolution has resulted in an armamentarium of targeted biologic agents, and several of these novel drugs have been shown to be active in patients with refractory cryoglobulinemia. This chapter reviews the clinical results and rationale of several emerging agents for cryoglobulinemia, including TNF inhibitors, the immunomodulator drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib.",
author = "Giampaolo Talamo and Maurizio Zangari",
year = "2012",
month = "4",
day = "1",
doi = "10.1007/978-88-470-1705-4_45",
language = "English (US)",
isbn = "8847017041",
volume = "9788847017054",
pages = "349--355",
booktitle = "HCV Infection and Cryoglobulinemia",
publisher = "Springer-Verlag Italia s.r.l.",

}

Talamo, G & Zangari, M 2012, Novel therapeutic approaches to cryoglobulinemia: Imatinib, infliximab, bortezomib, and beyond. in HCV Infection and Cryoglobulinemia. vol. 9788847017054, Springer-Verlag Italia s.r.l., pp. 349-355. https://doi.org/10.1007/978-88-470-1705-4_45

Novel therapeutic approaches to cryoglobulinemia : Imatinib, infliximab, bortezomib, and beyond. / Talamo, Giampaolo; Zangari, Maurizio.

HCV Infection and Cryoglobulinemia. Vol. 9788847017054 Springer-Verlag Italia s.r.l., 2012. p. 349-355.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Novel therapeutic approaches to cryoglobulinemia

T2 - Imatinib, infliximab, bortezomib, and beyond

AU - Talamo, Giampaolo

AU - Zangari, Maurizio

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Cryoglobulinemia is a rare disorder characterized by the development of leukocytoclastic necrotizing vasculitis. Currently, the conventional treatment of cryoglobulinemia in the absence of viral infection involves corticosteroids, immunosuppressive drugs, and plasma exchange. Patients with relapsed or refractory disease require additional therapies, but no established guidelines regarding the treatment of these patients are available. The recent molecular revolution has resulted in an armamentarium of targeted biologic agents, and several of these novel drugs have been shown to be active in patients with refractory cryoglobulinemia. This chapter reviews the clinical results and rationale of several emerging agents for cryoglobulinemia, including TNF inhibitors, the immunomodulator drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib.

AB - Cryoglobulinemia is a rare disorder characterized by the development of leukocytoclastic necrotizing vasculitis. Currently, the conventional treatment of cryoglobulinemia in the absence of viral infection involves corticosteroids, immunosuppressive drugs, and plasma exchange. Patients with relapsed or refractory disease require additional therapies, but no established guidelines regarding the treatment of these patients are available. The recent molecular revolution has resulted in an armamentarium of targeted biologic agents, and several of these novel drugs have been shown to be active in patients with refractory cryoglobulinemia. This chapter reviews the clinical results and rationale of several emerging agents for cryoglobulinemia, including TNF inhibitors, the immunomodulator drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib.

UR - http://www.scopus.com/inward/record.url?scp=84864934152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864934152&partnerID=8YFLogxK

U2 - 10.1007/978-88-470-1705-4_45

DO - 10.1007/978-88-470-1705-4_45

M3 - Chapter

AN - SCOPUS:84864934152

SN - 8847017041

SN - 9788847017047

VL - 9788847017054

SP - 349

EP - 355

BT - HCV Infection and Cryoglobulinemia

PB - Springer-Verlag Italia s.r.l.

ER -

Talamo G, Zangari M. Novel therapeutic approaches to cryoglobulinemia: Imatinib, infliximab, bortezomib, and beyond. In HCV Infection and Cryoglobulinemia. Vol. 9788847017054. Springer-Verlag Italia s.r.l. 2012. p. 349-355 https://doi.org/10.1007/978-88-470-1705-4_45